Bacac, M., Fauti, T., Sam, J., Colombetti, S., Weinzierl, T., Ouaret, D., Bodmer, W., Lehmann, S., Hofer, T., Hosse, R.J., Moessner, E., Ast, O., Bruenker, P., Grau-Richards, S., Schaller, T., Seidl, A., Gerdes, C., Perro, M., Nicolini, V., Steinhoff, N., Dudal, S., Neumann, S., von Hirschheydt, T., Jaeger, C., Saro, J., Karanikas, V., Klein, C. and Umana, P. (2016) A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. Clinical Cancer Research, 22, 3286-3297.
https://doi.org/10.1158/1078-0432.CCR-15-1696

has been cited by the following article:

• TITLE: Construction of Multi-Specific Antibody by Genetic Engineering and Its Progress in Tumor Therapy

  AUTHORS: Zhenqi Xu, Can Gao, Mengru Jian, Wei Du

  KEYWORDS: Genetically Engineered, Multi-Specific Antibody, Tumor Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 24, 2023

  ABSTRACT: Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.